NPPA has bought yet another list of molecules under DPCO, this time targeting the anti-infectives, followed by gastro and vaccines categories.
In a order on the NPPA site dated Sept 16, the pricing regulator has reduced the prices of 46 formulations. The highest cut has been to ciprofloxacin 500 and 250 mg, which is 65 per cent of the market of the released CP.
As per AIOCD data, these cuts will impact Ranbaxy the most (61.9 per cent), followed by Cipla (59.1 per cent) in terms of percentage of loss. Vaccine major Serum suffers a 67.1 per cent loss as well while Emcure will take a hit of 37.3 per cent.
